Physician profile
Talisa Eiko Forest
NPI 1154783447
$83,558.31
in general payments reported to CMS, 2019-2025
9 companies · $4,248 in 2025
The $4,248 reported for 2025 was more than what 87% of Retina Specialist providers received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $404 · 2021: $559 · 2022: $151 · 2023: $455 · 2024: $78K · 2025: $4,248.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Grant: $75K · Consulting Fee: $5,755 · Food and Beverage: $1,466 · Travel and Lodging: $224.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Grant | $75,000.00 |
| Consulting Fee | $5,755.00 |
| Food and Beverage | $1,465.63 |
| Travel and Lodging | $223.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Research LLC | $75,000.00 | 2024 | |
| Genentech USA, INC. | $6,815.18 | 2022-2025 | Vabysmo, Susvimo |
| Alcon Vision LLC | $531.57 | 2019-2021 | |
| Dutch Ophthalmic, USA | $419.52 | 2021-2024 | Tissueblue, Eva, Combined Machine |
| Oculus Surgical INC. | $312.13 | 2021-2025 | |
| Astellas Pharma US INC | $160.00 | 2024 | Izervay |
| Genentech, INC. | $129.17 | 2023-2025 | Vabysmo |
| Glaukos Corporation | $109.19 | 2021 | |
| Abbvie INC. | $81.55 | 2023-2025 | Ozurdex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Talisa Forest listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.